2024-03-14 16:21:05 ET
More on Molecular Partners
- Molecular Partners AG 2024 Q2 - Results - Earnings Call Presentation
- Molecular Partners says data from projected therapeutically active doses of MP0533 from Phase 1/2a trial to be presented in H1
- Molecular Partners, Orano to collaborate on RDT therapies for cancer
- Seeking Alpha’s Quant Rating on Molecular Partners
- Historical earnings data for Molecular Partners
Read the full article on Seeking Alpha
For further details see:
Molecular Partners GAAP EPS of -$1.89 beats by $0.14, revenue of $7.0M beats by $1.93M